Sign Up

Your Profile will be reviewed by Admin
TODAY : Advanced Search
Apr 2018


Grand Hyatt Washington 1000 H Street NW Washington , District of Columbia 20001
Tel: (202) 582-1234
Google Map

World Vaccine Congress Washington 2018






$1,600 - $3,950


Event Overview:

New vaccine technology is changing the whole industry

Make sure you are at the forefront of the vaccines industry. No matter where your interest lies, we have content, networking and potential partners for you.

By bringing ten events together under one roof, you get to choose the sessions which are the most applicable to help your business plan for the future of vaccine research, development and manufacture.

Take just four days out of the office to meet over 1,000+ potential customers who need to find solutions to their challenges.

Build four days of totally tailored content and attendees.  

Exhibitor / Sponsor Information:

What this means for your business:
Emerging science, technologies and collaborations are needed to make the necessary moves forward. As a provider of solutions to these issues, the event will provide a space for you to get in front of potential new customers from all walks of the vaccine industry.

Pursue and partner

    Thousands of formal and informal meetings over just three days
    30+ scientific posters
    Three engaging networking lunches
    Two networking drinks receptions
    ViE Awards and Gala Dinner

 Your customers are here to:

    Hear insights from the world’s leading thinkers, practitioners and process disrupters
    Evaluate and buy the latest technologies
    Create new partnerships and gain investment
    Have fun and do business

What a great opportunity to:

    Debut new solutions
    Improve your brand awareness
    Meet new prospective clients
    Maintain relationships


Apr 2   

Pre-Congress Workshops A & C


Workshop A: Advances in using structure-based knowledge for smarter vaccine designs

Structure-based vaccines are designed on the rationale that atomic-level information on antibody-antigen interactions can provide critical insight to assist the development of immunogens capable of inducing protection against pathogens. Structure-based vaccines have become a much-anticipated field over the years with increasingly more preclinical and clinical staged developments. This workshop focuses on recent advances and their application in providing protection against infectious diseases.

Progress in Stabilized Pre-fusion Glycoprotein Vaccines for Paramyxoviruses & HIV-1 

Using structural based vaccine design to target flavivirus infections: Zika and Dengue

GSK’s CMV structural biology research 

Discussion with all speakers

Dr Peter Kwong, Chief, Structural Biology Section, NIH

Dr Andrea Carfi, Senior Director, Antigen Design and Project Leader,Valera LLC

Dr Hans Langedijk, Director of Subunit Vaccine Design, Janssen Vaccines & Prevention B.V.

Felix Rey, Head of Structures, Institut Pasteur

Dr Sumana Chandramouli, Laboratory Head, Preclinical R&D, GSK Vaccines

Pre-Congress Workshops B & D


Workshop B: Incorporating passive immunization with active immunization – The role and use mABs for infectious diseases

Should there really be a distinction between passive and active immunization when responding to diseases and infections therapeutically? Join this workshop to understand how these treatments are increasingly combined and the role of both passive and active immunization in future.

An overview of the scientific rationale & landscape survey of antibodies in preclinical and clinical development for infectious diseases 

RSV and bacterial (Sa and Pa) prophylactic monoclonals in development 

Current Sa antibodies used effectively for prophylaxis

True Human™ antibody therapy against C. difficile

Moderator: Surya Sankuratri, Executive Director, Merck

Dr Steve Projan, Senior Vice President of Innovative Medicines, Research and Development and Head of Infectious Diseases and Vaccines,MedImmune Inc

Dr Todd Black, Executive Director, Infectious Diseases, Merck Research Laboratory

Dr Sushma Shivaswamy, Vice President, Research and Development,XBiotech

Dr Eszter Nagy, Co-Founder, President and CSO, Arsanis Inc


Networking Lunch


Pre-Congress Workshops A & C


Workshop C: Market access & regulatory challenges in vaccines

The market access landscape for vaccines is more complex than most. Various obstacles are creating a disproportionate move away from investing in preventative interventions and vaccines. Recommendation from the ACIP is an important step towards funding and getting a vaccine to market. 

Join us at the workshop to understand the key components of the ACIPs decisions to recommend and fund and how industry can facilitate this process. Learn how to cope with the obstacles to make sure we get optimal value for our vaccines and discover the pit falls to avoid when launching a new vaccine.

Recommendations and Funding: What are the key components to the ACIPs evaluation of vaccines?

The Value of Vaccination 

Accelerating Access to Vaccines: A manufacturer’s perspective?

Jim Wassil, Vice President, Business Unit Lead, Vaccines, Global Health and Value, Pfizer

Dr David Bloom, Professor of Economics and Demography, Harvard T.H. Chan School of Public Health

Dr Arthur Reingold, Professor and Division Head Epidemiology, Former ACIP Member, UC Berkeley School of Public Health

Pre-Congress Workshops B & D


Workshop D:The role of vaccines in preventing outbreaks, through natural causes or biothreats: The WHO blueprint

It only takes natural outbreaks like the Ebola and Zika viruses to highlight the danger and fragile balance we live in. To ensure global and international security, important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments. Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.

Public-private partnerships for pandemic influenza and emerging infectious disease vaccine preparedness and response

The WHO blueprint: Nipah, MERS, LASSA, Zika, Chik

Modelling for dangerous pathogens and estimating vaccine efficacy

Dr Ruben Donis, Deputy Director of the Division of Influenza and Emerging Infectious Diseases, HHS - ASPR - BARDA

Dr Ira Longini, Professor & Co-director, Center for Statistics and Quantitative Infectious Diseases (CSQUID) Emerging Pathogens Institute, University of Florida

Ana Maria Henao Restrepo, Implementation Research and Economic Analysis, Initiative for Vaccine Research, World Health Organization

Apr 3   


Chair’s opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation


Immunization across the lifespan – What will it take? A WHO perspective

Building routine influenza immunization programs in low-resource settings

Vaccinations in adulthood: An important role in public health and in reducing morbidity and mortality rates

Why are adults often behind in many vaccinations?

Dr Justin R Ortiz, Former Medical Officer, Initiative for Vaccine Research for WHO & Associate Professor of Medicine, University of Maryland


Adjuvant technology and its impact on vaccine development

Analysis of the importance and role of innate immunity

Formulation of novel adjuvant combinations

Dr Carl Alving, Former Chief of Adjuvant and Antigen Research & Emeritus Senior Scientist, Walter Reed Army Institute Of Research


Designing and building the next generation of vaccine adjuvants

Discovery of adjuvants, their optimal delivery and how they advance into clinical evaluation and assessment of their performance

Creating robust and scalable formulations

Negotiating a path to potential approval

Dr Derek O'Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines


What it takes to get a vaccine from research to near elimination of H influenza type b (Hib) diseases globally: Saving 7 million lives by 2020

How the pivotal PRP-OMP conjugate vaccine efficacy trial was designed and conducted, leading to the licensure of the vaccine (Pedvax Hib)

Challenges and triumphs – lessons learned that can be applied to today’s vaccine research and trials for global access

Dr Mathuram Santosham, Professor, Johns Hopkins University


Networking coffee break



Choose two roundtable sessions back-to-back and explore a range of topical issues that can be discussed with other thought leaders at a more interactive basis – 40 min per roundtable

Aligning Sponsor/CRO/Laboratory Communication for Esoteric Laboratory Services

Dr Wayne Hogrefe, VP, Vaccines, Q² Solutions

Animal component free media: What’s critical?

Jeremy Gillespie, Global sales Director, Kerry

Applying next generation sequencing to assess immune-mediated drug hypersensitivity

Dr Masahide Yano, Research Scientist, U.S. Food and Drug Administration

Are you ready for Phase II?

Marc Hoffman, CMO, Celerion

Best practices for a Successful CRO/Pharma partnership for Vaccine Clinical Studies

Title TBC

Dr Darin Seehafer, Clinical Scientist/Program Director, PRA Health Sciences

Better strategy to streamline collaboration between development teams (from process to analytical/formulation) and manufacture

Dr KC Cheng, Senior Director - Analytical and Formulation Development, NIAID, NIH & University of Kansas

Clinical Development & trials: Conducting clinical trials in low resource settings

Developing more effective vaccines for emerging/re-emerging pandemic threats

Senior representative, ClinicalRM TBC

Dr James Cummings, Vice President, Clinical Development and Translational Medicine, Novavax

DNA, live vectors, adjuvanted vaccines. 30 years later, are they inter changeable or is there a specific use for each?

Dr Nathalie Garcon, CEO/CSO, BIOASTER

How can we actually apply big data and AI into smarter vaccine design?

How to measure and develop dual use vaccines?

Managing your cold chain – Lessons learned from the Ebola clinical trials

Geoffrey Glauser, Senior Consultant Supply Chain, HHS - ASPR - BARDA

Non-clinical safety considerations when working with live virus and LNP based vaccines

Dr Lisa Plitnick, Senior Principal Scientist, Vaccines Therapeutic Area Lead, Safety Assessment and Laboratory Animal Resources, Merck Research Laboratories

Strategies to effectively identify and target neoantigens in solid tumors

Dr Philip Arlen, President and Chief Executive Officer, Precision Biologics Inc

The human challenge testing paradigm

Bruno Speder, Head of Clinical Regulatory Affairs, SGS – Life Science Services

The use of ePRO solutions and platforms in vaccine studies

Jason Berg, Director, Project Management, PPD

Unexpected drivers of performance; doses per vaccine vial

Mr Robert Steinglass, Director, Immunization Center, John Snow Inc

Vaccines, outbreaks, and pregnancy: How vaccine development and deployment can better meets the needs of pregnant women and their offspring

Dr Ruth Faden, Founder, Johns Hopkins Berman Institute of Bioethics

Dr Carleigh Krubiner, Research Scholar, Johns Hopkins Berman Institute of Bioethics


Networking Lunch & Poster Session



Plenary panel: Responding to the next emerging disease globally

Dr Peter Hotez, Dean, National School of Tropical Medicine, Director, Texas Children’s Hospital Center, Baylor College of Medicine

Dr Nicole Lurie, Strategic Advisor to CEO, CEPI

Dr Ripley Ballou, VP & Head, GSK Global Vaccines US R&D Center, GSK Vaccines

Dr Rahul Singhvi, Chief Operating Officer, Takeda Vaccines

Prof Stanley Plotkin, Emeritus Professor, University of Pennsylvania School Of Medicine


Enabling guidance from the World Health Organization

-          WHO’s target product profiles for outbreak vaccine development

-          Data and sample sharing in emergencies and during the inter-emergency period

Dr Vasee Moorthy, Coordinator, Research, Ethics, Knowledge Uptake, Department of Information, Evidence and Research, & Team Leader, R&D Blueprint, World Health Organization


Networking coffee break


Executive cancer panel: How will recent breakthroughs in immuno-oncology determine cancer vaccine and combinational treatments?

The significance of check point inhibitors, oncolytic viruses neoantigens, CAR T-cells and ACT on cancer immunotherapy progress

Supporting evidence from combinational studies

The role of cancer vaccines in the future of combinational approaches

Dr Roy Baynes, SVP of Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

Dr Nir Hacohen, Director of the Center for Cancer Immunology and Co-Director of the Center for Cell Circuits, Broad Institute and Massachusetts General Hospital

Dr Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Company


The role of vaccines to combat antibiotic-resistant bacteria

Insights and recommendations from the national vaccine advisory committee and Chatham house

Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship

Dr Bruce Gellin, President, Global Immunization, Sabin Vaccine Institute


Trispecific abs and novel platforms to prevent HIV and other viral infections

Dr Gary Nabel, Chief Scientific Officer & Senior Vice President Head, North America R&D Hub, Sanofi Pasteur


Chair’s closing remarks and close of congress day 1

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation





Apr 4   


Chair’s opening remarks

Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines


Chair’s opening remarks

Amy Finan, Chief Executive Officer, Sabin Vaccine Institute


Chair’s opening remarks


Chair’s opening remarks


Chair’s opening remarks

Dr Saad B Omer, William H. Foege Professor of Global Health Professor of Epidemiology & Pediatrics, Emory University - School of Medicine


Chair’s opening remarks

Dr Niranjan Sardesai, COO, Inovio Pharmaceuticals


Chair’s opening remarks


Chair’s opening remarks

Dr Cyril G Gay, Senior National Program Leader, A.R.S. National Programs


Chair’s opening remarks


Chair’s opening remarks












Novel adjuvants: What’s needed and how to get them approved?

Future of adjuvants – what is needed?

The need for a better strategy for a rational design

Developing adjuvants to improve existing vaccines & reduce the amount of vaccine antigen needed

New mechanism of adjuvant; Inducible adjuvant mediated by multiple, but specific pathways

Dr Ken Ishii, Professor and Project Leader,Osaka U.i

Dr Arnaud Didierlaurent, Head Adjuvant Platform, GSK Vaccines

Dr Dan Stinchcomb, CSO, Infectious Disease Research Institute

Dr Nathalie Garcon, CEO/CSO, BIOASTER


Panel: Current status of vaccine confidence around the world

Highlight current global issues surrounding confidence, EU ruling, low confidence in France, US measles epidemic

How to talk to public

Dispelling rumours

Could we reverse global development goals?

Moderator: Dr Saad B Omer, William H. Foege Professor of Global Health Professor of Epidemiology & Pediatrics, Emory University - School of Medicine

Dr Peter Hotez, Dean, National School of Tropical Medicine, Director, Texas Children’s Hospital Center, Baylor College of Medicine

Dr Paul Offit, Chief of Infectious Diseases, & Director of the Vaccine Education Center,Childrens Hospital of Pennsylvania

Dr Heidi Larson, Professor of Anthropology, Risk and Decision Science, London School of Hygiene and Tropical Medicine


Structure guided design of a vaccine for RSV

Dr Barney Graham, Deputy Director of Vaccine Research Center, National Institute of Allergy and Infectious Diseases


Vaccine supply chains in low resource environments: past, present and future perspectives

The most fully scrutinized public sector vaccine supply chain are in the least developed countries; 

Supply chain strengths and weakness will be demonstrated - there are plenty of both;

Implications for the future for vaccine developers and manufactures will highlighted.

James Cheyne, Independent Supply Chain Consultant Co-Founder of WHO's Cold Chain Unit, Health Service Logistics


VLA 1601, a jointly-developed vaccine candidate against Zika based on a well-proven technology platform

·         Medical need and trends on Zika epidemiology

·         Vaccine design and characterization

·         Ongoing Phase I in the US and development outlook

Matthew Duchars, VP, Product Development,Emergent BioSolutions

Dr Wolfgang Bender, Chief Medical Officer,Valneva


What’s next after PD1? Next generation checkpoint inhibitors including anti-TGF-beta

A deeper look at TGF-beta as a checkpoint inhibitor.

What are its effects on tumour growth and other cell types?

Synergy with vaccines and PD1 checkpoint inhibitors.

Brief look at other novel checkpoints, regulatory cells and cytokines; LAG3, Tim3

Dr Jay A. Berzofsky, Branch Chief, Vaccine Branch, National Cancer Institute - NIH


Areas of interest for big pharma: External collaborative research and partnering opportunities for vaccine development

More speakers from Merck, Pfizer, biotechs and academics to join

Dr Philippe Denoel, Director of External R and D, Innovation, Scientific Affairs and Opportunities Collaborations for Public Funding, GSK Vaccines

Dr Roman Chicz, Associate Vice President and Global Head Of External Research and Development, Sanofi Pasteur

Dr Eliav Barr, Senior Vice President, Infectious Diseases and Vaccines Clinical Development,Merck Research Laboratories

Dr Cristina Cassetti, Branch Chief Virology Branch Division of Microbiology and Infectious Diseases, National Institutes of Health (NIH)


Rational design of veterinary vaccines, is it less established than human vaccines?

Strategy when conventional vaccines don’t work

Can vaccines alone eradicate? The need to combine treatments outside of vaccines with alternative approaches

Dr Mahesh Kumar, Vice President, Global Biologics Research, Zoetis


The Human Vaccines Project: Harnessing recent technological advances in the biomedical and computational sciences to accelerate vaccine development

Deciphering the human immunome to facilitate diagnostic, vaccine, and therapeutic discovery

Interpreting immunogenicity to enable induction of specific and durable protective immune responses

Towards a universal influenza vaccine

Wayne C Koff, President and CEO, The Human Vaccines Project


What can we learn from mAB bioprocessing to vaccines to make more vaccines? From R&D to full scale manufacturing and worldwide distribution

The transition from lab to manufacturing and large-scale production of low cost vaccines globally

Dr Don Gerson, CEO, Pnuvax Inc




Achieving an effective balance of attenuation and immunogenicity for RSV live attenuated vaccines (LAV)

·         Engineering RSV LAV strains with enhanced immunogenicity using a multi-faceted, rational mutagenesis approach

·         Enhancing expression of the pre-fusion conformation of the RSV fusion (F) protein

·         Using genetic mapping to identify residues that correlate with pre-fusion antigen maintenance and thermal stability of infectivity into LAV candidates

·         Candidates exhibiting elevated pre-fusion antigen levels, thermal stability, immunogenicity, and efficacy

Dr Martin Moore, Associate Professor, Interim Director of Research, Pediatric Infectious Diseases, Emory University Children’s Center


MVA-VLP as a Plug and Play platform for development of safe and effective single dose vaccines for emerging infectious diseases, preclinical data for Zika, Ebola and Lassa as examples

Dr Farshad Guirakhoo, CSO, GeoVax, Inc.


Panel Discussion: challenges to enhancing the therapeutic effectiveness of immune checkpoint antagonists with checkpoint agonists and inhibitors of immuno-metabolic pathways

Activating the antitumor immune T cell response through agonistic targets such as CD137 and OX40

Understanding the pathways used to create immune suppression and techniques to slow down immune suppression

What makes t-cell agonists so hard to work with vs checkpoint inhibitors?

Moderator: Dr Rakesh Dixit, Vice President R&D, Global Head, Biologics Safety Assessment, MedImmune Inc

Dr Hyam Levitsky, Executive Vice President and Chief Scientific Officer, Juno Therapeutics

Dr Ching Ching Leow, AVP, Immuno-Oncology Clinical Development, Eli Lilly and Company


Success Factors for managing a scalable global clinical supply chain system

Managing vaccine supply chains at a global level; setting the right inventory levels, avoiding stock outs, managing supply and demand

Challenges associated specifically with vaccine supply;

Long lead times

Heavy focus on Quality Assurance

Complying with global regulation

Keeping up with constant improvements in the manufacturing process

Matthew Burt, Vaccine Supply Chain Director,,Pfizer


Technology showcase 1

Vesicular stomatitis virus vectors – A promising vaccine platform

Heinz Feldmann, Chief, Laboratory of Virology Chief, Disease Modeling and Transmission Section, NIH


Vectored herpesvirus vaccines and novel approaches, for their attenuation and continued efficacy

Professor Klaus Osterrieder, Managing Director, Institute of Virology, Department of Veterinary Medicine, Freie Universitt Berlin


Immune profiling in the context of TB and Malaria vaccination

Dr Robert Seder, Chief of the Cellular Immunology Section, NIAID, NIH


Practical solutions enabling rapid production of viral based therapies

Parrish Galliher, Chief Technology Officer, GE Healthcare


Technology showcase 2

Chimpanzee adenovirus vector vaccine technology 

Dr Sally Mossman, VP, Head Discovery Performance Unit, US, GSK Vaccines



A Plug-and-Play Technology Platform to Expedite the Production of Vaccines for Biodefense and Emerging Infectious Diseases

·         The potency and functionality of our platform with data from studies with highly pathological avian influenza (HPAI) and MERS-CoV vaccines

Dr Uwe Staerz, Chief Scientific Officer Chairman, Greffex Inc


An overview of the use of Sentinel to assess the safety of vaccines


Have we made enough progress in overcoming the unique challenges in conducting vaccine clinical trials in Asia?

Use of surrogate endpoints, differential efficacy / safety in diverse populations, accurate measures of exposure

Lynlee Burton, Director of Project Delivery - Vaccines, PRA Health Sciences


Optimizing supply chains to meet the demands of an increasingly large and costly portfolio of vaccines

Anup Akkihal, Chief Executive, Logistimo


Panel: Pfizer’s RSV vaccine program

·         Research background

·         Pre-clinical results and clinical plan

Dr Kena Swanson, Senior Principal Scientist, Viral Vaccines, Research Lead, RSV, Pfizer

Beate Schmoele-Thoma, Senior Director Vaccine Clinical Research and Development, Clinical Lead, RSV, Pfizer

Dr Philip Dormitzer, Vice President and CSO, Viral Vaccines, Pfizer


Technology showcase 3

Nanodisc technology for personalized cancer vaccination

Prof James Moon, Assistant Professor of Biomedical Informatics, University of Michigan


Controlling zoonotic diseases in the developing world


Creating a detailed understanding of how the immune responds to foreign pathogens or self-antigens and developing tools for prediction


Latest advancements in production process intensification to support demand for affordable vaccines

Use of fixed-bed bioreactors

Development of microfacilities

Dr Ahd Hamidi, Project Director, Batavia Biosciences


A single-dose live-attenuated Zika vaccine

·         3’UTR 10-nucleotide deletion

·         Prevents infection in rhesus macaques & utero transmission in pregnant mice

·         Protects testis and sperm count damage in mice

·         Protective immunity within two weeks in rhesus macaques

·         Durable immunity with potential life-time protection

·         Excellent safety profile in mice and non-human primates

Pei-Yong Shi, Kempner Professor of Human Genetics, University of Texas Medical Branch


Technology showcase 4

ImplaVaxTM – Unique needle free solid dose vaccine platform delivering enhanced immunogenicity with ultimate convenience and no cold chain

David Hipkiss, Chief Executive Officer, Enesi Pharma Limited


Overview of cell culture & new expression systems improving vaccine bioprocessing


Networking coffee break




Can we use moderately effective vaccines for safe public use? Using Dengue as an example

Moderator: Dr Duane J Gubler, Emeritus Professor, Programme in Emerging Infectious Diseases, Duke-NUS Graduate Medical School

Dr Brad Gessner, VP for Scientific Affairs at AMP, Faculty at U. Maryland/Centers for Vaccine Development & VP and Director, Global Pneumococcal, Pfizer

Dr Stephen Whitehead, Senior Associate Scientist, NIAID, NIH

Dr Scott Halstead, Adjunct Professor, Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences


Driving the immunization supply chain with data

Digital solutions and other innovations for improving data visibility, including case study examples

How to build a culture of data use

Future directions in improving the visibility and use of data

Edward Wilson, Director, Center for Health Logistics, John Snow Inc


Limitations of randomized controlled clinical trials in vaccine development

Dr Steven Black, Professor of Pediatrics, Center for Global Health, University of Cincinnati Children’s Hospital in Ohio


Panel: Improving active vaccine & immunotherapy safety surveillance in resource-limited settings

The use of self-control approaches for investigation of vaccine adverse events


The need for pharmacoepidemiologic studies to evaluate immune-mediated reaction (IMR) signals in response to checkpoint inhibitor treatment

Moderator: Dr Walter Straus, Associate Vice President, Therapeutic Area Head, Clinical Safety and Risk Management, Merck Research Laboratories

Dr Hector Izurieta, Epidemiologist, Immediate Office of the Director. Office of Biostatistics and Epidemiology, CBER, U.S. Federal Drug Administration

Dr Raphael Pareschi, Pharmacovigilance Associate Director, PV Country lead deputy,,Merck & Co

Rodrigo Ruiz, Head of Country Pharmacovigilance Mexico, Bristol-Myers Squibb De Mexico

Dr Jens-Ulrich Stegmann, Vice President Head Clinical Safety and Pharmacovigilance, G.S.K Biologicals


PD-1 antibodies are transforming cancer therapy both as monotherapies and in combination

PD-1 antibody monotherapy indications continue to expand

PD-1 antibody has shown potential important activity when combined with:

Standard therapies e.g. chemotherapy

Targeted therapies e.g. with TKIs

Other immune modifying therapies e.g. IDO-1 inhibitors

Oncolytic viruses e.g. TVEC

Precision medicine will be increasingly important in patient selection

Dr Roy Baynes, SVP of Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories


The RSV F Nanoparticle Vaccine for Infants via Maternal Immunization in Phase 3: Rationale and Update

Dr Gregory Glenn, President, Research and Development, Novavax


Technology showcase 5

Novel nanoparticle formulations for delivery of protein or RNA vaccines

Dr Dan Stinchcomb, CSO, Infectious Disease Research Institute


Immunomodulators: Rationale for targeting the innate immune response when vaccines aren’t effective

Role of innate immunity

Immunostimulants as preventative and therapeutic agents

Recent developments in veterinary immunomodulators

Dr Robert Zolynas, Vice President, Bayer Animal Health


Biomarkers of vaccine safety

The need for specific trial design

Systemic vs local markers

The experience of Biovacsafe

Giuseppe Del Giudice, Translational Science Leader, GSK


Comparing traditional vaccine manufacturing to mRNA vaccine manufacturing

Dr Hari Pujar, Vice President Technical Development and Manufacturing, Moderna Therapeutics


Technology showcase 6: Salipro nano-membrane particles - A platform for antigen stabilization and vaccine development

Dr Robin Löving, CSO, Salipro Biotech AB


A comprehensive analysis of combination studies in immuno-oncology

Summary of all IO agents, targets and companies

Overview of ongoing PD-1 combination studies

Trends and areas to enhance efficiencies

Role of Philanthropy in IO

Dr Aiman Shalabi, Chief Medical Officer,Cancer Research Institute


Building further on Viroclinics Ferret model with novel insights: Transmission of HRSV in Immunocompromised ferrets

·         Demonstration of efficient transmission of human respiratory syncytial virus (HRSV) from immunocompromised ferrets to both immunocompromised and immunocompetent ferrets

·         Research findings were collected by applying several assays including Sequencing, PCR, Virus Culture/Titration. Furthermore, histo pathological changes of respiratory tissues from donor and contact ferrets were demonstrated by standard and immunohistochemistry

·         A high transmission rate of HRSV was found and more …

Dr Koert Stittelaar, Director Preclinical Services, Viroclinics Biosciences


Overcoming challenges in seasonal vaccine studies, including maternal immunization

Marty Anderson, Executive Director, Clinical Development - GenMed, Syneos Health


Redesigning immunization supply chains in low and middle-income countries: a case study

What is the current scope of the problem

What level of change is needed

Promising examples of change in sub-Saharan Africa

Ms Emily Bancroft, President, VillageReach


Technology showcase 7: Lentiviral vectors as a novel platform for T-cells vaccines

Dr Pierre Charneau, Head, TheraVectys-Institut Pasteur Joint-Lab


Self-amplifying RNA technology

Dr Jeffrey Ulmer, Head, Preclinical R&D US,GSK Vaccines


Principles of broad and potent antiviral human antibodies: Insights for vaccine design

Isolating and studying human antiviral mAbs and the basis for their activity

Understanding of the chemical and physical basis for molecular recognition of viral surface proteins

Building predictive molecular models that can be used for vaccine design

Dr James Crowe, Director of Vanderbilt Vaccine Center, Vanderbilt Vaccine Center


Bridging the Global Health Gap – Viral and bacterial vaccine development at Intravacc

Dr Wilfried Bakker, Program Manager Viral Vaccines, Intravacc



Investor panel: Hear from different VCs to better understand what they are looking for before they invest

More VCs to be announced shortly

Stephen Nagler, Executive Director, MedPro Investors LLC


ExpreS2 – an insect cell based vaccine production system suitable for difficult-to-express proteins

Dr Max Søgaard, Director process dev,ExpreS2ion Biotechnologies



A CMV vaccine based on non-replicating lymphocytic choriomeningitis virus vectors expressing gB and pp65

12 months Phase I data supporting a Phase 2 randomized, placebo-controlled trial in CMV-negative recipient patients awaiting kidney transplantation from CMV-positive donors

Camille Kotton, Clinical Director, Transplant and Immunocompromised Host Infectious Diseases, Massachusetts General Hospital


Industry perspective: Improving your supply chain strategy and system design


Landscape analysis of RSV vaccine development and future implications

Dr Natalie Mazur, Clinician-Investigator,Wilhelmina Children’s Hospital in Utrecht


Rapid and efficient development of combination therapies through a novel cancer immunotherapy platform.

Introduction to Morpheus; a novel cancer immunotherapy platform

How to go about selecting a combination study

Potential for use across several indications

Dr Erin Karski, Associate Medical Director,Genentech


Tools for clinical data visualization that improve efficacy and accuracy of safety assessment and allow firms to keep up with changing regulatory requirements


Incorporating new and effective adjuvants into your vaccine development


Induction of antigen specific immune tolerance with vaccination

Dr Matthias Von Herrath, Professor in Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology


Analytical characterization of aluminum adsorbed vaccines: Stability indicating methods for product release

What general guidance is there on release and stability test methods for aluminum adsorbed vaccines?  

Understanding of the antigen stability following adsorption

Reviewing potential release tests and proposing a panel of stability indicating tests for aluminum adsorbed vaccines

Wendy Saffell-Clemmer, Director - Research,Baxter BioPharma Solutions



A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among the elderly

We searched the literature for clinical trials (CTs) including new adjuvant systems (AS01, AS02, AS03, or MF59), used in people of 50 years and older, published between January 1995 and September 2017.

12 CTs were retained on AS01/AS02, AS03 and MF59 adjuvants, respectively, covering 92,123 subjects

This systematic literature review showed no overall increase in SAEs, fatalities, or unsolicited AEs following newly adjuvanted vaccines.

Higher rates for local or general AEs were observed for all newly adjuvanted vaccines, but AEs were mostly mild and transient.

Thomas Verstraeten, Owner, P95


Comparisons between QIV and Vaxart’s oral vaccine for protection against influenza challenge in humans

Dr Sean Tucker, CSO and VP Research, Vaxart


Session title TBC

Senior representative, Desert King


Networking Lunch & Poster Session








Characterization of the immune response induced by plant-made influenza vaccines

Immunogenicity of a plant-derived quadrivalent VLP vaccine in adults and the elderly

·         Phase 2 clinical results on QIV seasonal VLPs in healthy adults and elderly

·         Comparison of humoral and cell-mediated immune responses induced by VLPs

Dr Brian Ward, Medical Officer, Medicago


Considerations and challenges in pre-clinical safety assessment of vaccines and passive immunization strategies

Respiratory Syncytial Virus Infection in Adults and Pediatric populations

Demonstration of disease exacerbation in an animal model

Species selection

Monoclonal antibodies with half-life extension mutations

Dr Clifford Sachs, Director, R&D Toxicology,MedImmune Inc


Design and implementation of clinical trials in an emerging epidemic: Flavivirus Case Study

Clinical development challenges associated with the design and conduct of emerging epidemic trials

Current status of Zika Vaccine candidates in Clinical Development

Geographical Considerations: Epidemiology v Trial Locations

Considerations for Zika Vaccine Clinical Development Strategy

Dr Grace Chen, Deputy Chief, National Institutes of Health


Design and implementation of clinical trials in an emerging epidemic: Flavivirus Case Study

·         Clinical development challenges associated with the design and conduct of emerging epidemic trials

·         Current status of Zika Vaccine candidates in Clinical Development

·         Geographical Considerations: Epidemiology v Trial Locations

·         Considerations for Zika Vaccine Clinical Development Strategy


Overcoming Key Supply Chain Challenges for Vaccine Shipments

Establishing a strong global network increases the strength of your supply chain

Explore the latest technological advances in packaging and tracking for complete end to end visibility

Learn how performing a detailed risk assessment, including lane verification, helps to ensure a smoother and less risk-sensitive shipment process

Paddy Hanlon, V.P. Global Key Accounts,Marken


State of the art and novel approaches to T Cell Vaccines

How have recent advances in immunotherapy provided a path forward for T-Cell Vaccines?

Biomarkers for T-cell strategies

Dr Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Company


The formation of new companies developing infectious disease vaccines


The impact of the current vaccine industry ecosystem on funding for vaccine start-ups

Looking beyond venture capital for early stage funding

Timothy Cooke, Chief Executive Officer,NovaDigm Therapeutics


The need to mass inoculate: What delivery systems have we developed that can cater for the different animal groups?


Integrated Immune Monitoring Solutions for Preclinical and Clinical Development of Immunotherapeutics


Review of the current alternative vaccine delivery methods and how their effectiveness is assessed

The advantages and progression of up taking alternative delivery systems and packaging

The logistical challenges to consider for developing countries

How to make new technologies applicable and build a stronger business case to be used

Total system effectiveness: Cost modelling of delivery systems

Darin Zehrung, Portfolio Leader of Vaccine and Pharmaceutical Delivery Technologies and Senior Technical Officer, Path


FluoroSpot in vaccine research: Investigating polyfunctional T cell responses and B cell cross-reactivity


High-resolution profiling of antibody responses to arrays of peptides

Applications in vaccines, oncology, autoimmune disorders, antibody discovery


How can vaccines and vector control be integrated and used synergistically in a control program

·         Clinical development challenges associated with the design and conduct of emerging epidemic trials

·         Current status of Zika Vaccine candidates in Clinical Development

·         Geographical Considerations: Epidemiology v Trial Locations

·         Considerations for Zika Vaccine Clinical Development Strategy

Moderator: Dr Thomas W Scott, Distinguished Professor, University of California Davis

Dr Robert Reiner, Assistant Professor, Global Health, University Of Washington

Dr David L. Smith, Professor in the Department of Epidemiology, Johns Hopkins and the Center for Disease Dynamics

Dr Ira Longini, Professor & Co-director, Center for Statistics and Quantitative Infectious Diseases (CSQUID) Emerging Pathogens Institute, University of Florida


Innovations in cold chain equipment – preventing freezing in the vaccine cold chain using wireless remote temperature monitoring

Many newer, more expensive vaccines are freeze / heat sensitive – so monitoring and maintenance of cold chain equipment is critical.

High-income as well as low- and middle-income countries suffer when cold chain equipment fails and tempertatures damage or destroy vaccines.

Real-time temperature monitoring allows for quick detection of problems, rapid response to save vaccines, intelligent maintenance, and more.

At a high level, the data collected enables evidence-based budgeting, procurement, equipment placement, and effective planning.

Shahrzad Yavari, Program Director, Nexleaf Analytics


Safety assessment during the clinical development phase of a vaccine

Capturing of data

Relevance of causality assessment

When to build a benefit/risk assessment

Different populations vs different approaches

Dr Jens-Ulrich Stegmann, Vice President Head Clinical Safety and Pharmacovigilance, G.S.K Biologicals


Synergy of DNA Vaccines with checkpoint inhibitors

Selection of appropriate vaccine antigens for prostate cancer

Updates from ongoing translational trials of DNA vaccines in prostate cancer

Dr Douglas Mcneel, Chief Scientific Founder and Head of M.V.I. Scientific Advisory Board,Madison Vaccines Inc.


Utilization of eDiaries in Vaccine Studies: Where are we now?

Dr Cynthia Dukes, Vice President - Global Project Management, ICON

Wilhelm (Willie) Muehlhausen, VP eCOA & Innovation, ICON


Utilizing human challenge studies to accelerate the development of respiratory vaccines

Session title TBC

Andrew Catchpole, Scientific and Operations Director, hVIVO


Innovative mechanisms in funding vaccine technology: A PPP model for international partnerships that bring Japanese innovation, investment and leadership

How will current investments plan contribute to IDs, NTDs and vaccine development?

The importance of cross collaborations

B.T. Slingsby, Chief Executive Officer and Executive Director, Global Health Innovative Technology Fund


Bench to Market: Challenges and opportunities in the commercialization of academic vaccine candidates to the marketplace

Alan Young, CSO, Medgene Labs


Neoantigens versus tumour associated antigens: What are their relative roles as targets for cancer immunity?

While there is clear evidence that mutation associated neoantigens provide relevant targets, the role of tumor associated antigens remains to be validated.

Tumor viruses allow us to have our cake and eat it- they are tumor specific, yet shared.

New platforms for sensitive and specific assessment of t cell responses to cancer open the door to a broader range of immunotherapies.

Dr Drew Pardoll, Director, Bloomberg~Kimmel Institute for Cancer Immunotherapy Professor of Oncology, John Hopkins University


Creating the next generation of vaccines and immunotherapies by mimicking an infection to enhance the immune response

Illustrating how the delivery of sustained release vaccine depots via microneedle patch improves immunogenicity

Logistical conquest in easy administration, shelf life stability and only minutes of wear time

Current progress with an in-house influenza vaccine and partnered programs to advance formulation for optimal patient uptake

Michael A. Schrader, Co-Founder and Chief Executive Officer, Vaxess Technologies, Inc


Solutions for intradermal administration & clinical experience with the MicronJet600R

Dr Gregory Glenn, President, Research and Development, Novavax



Development of a novel prophylactic vaccine for the prevention of Lyme disease: Phase I results of Valneva’s Lyme vaccine candidate VLA15 and development outlook

Background and medical need

Vaccine design including preclinical data for VLA15        

Phase I results and development outlook

Thomas Lingelbach, President and Chief Executive Officer, Valneva


Engaging private sector innovators to create sustainable change at scale in low resource environments.

Bringing business acumen and innovation to bear to save lives and create sustainable health systems

What are the biggest supply chain related obstacles to reaching all children with life-saving vaccines

How can partnerships be created that provide a win-win for both the public and private sectors

Jeffrey Rowland, Director, Global Operational Partnerships, Gavi, The Vaccine Alliance


Hollow microneedles for use in delivery of cancer vaccines

Delivery to appropriate target tissue is critical to control the safety and effectiveness of vaccines 

We have used a new product developed by 3M to consistently for intradermal delivery of a cellular vaccine 

The unit is easy to load and deliver the product 

Our autologous DC vaccine using this product has shown evidence of efficacy for newly diagnosed glioblastoma patients.

Dr Allan B Dietz, Director, Immune, Progenitor, and Cell Therapeutics (IMPACT), Division of Transfusion Medicine, Mayo Clinic and Foundation


Influenza vaccines immunological assessment

Prof Emanuele Montomoli, Prof in Public Health University of Siena & CSO, VisMederi


Vaccine pharmacovigilance: the once and future challenges

Data sources for vaccine safety are advancing; the introduction of more sophisticated data sources and methods may help address some of the shortcomings of the most established pharmacovigilance tools.

The introduction of novel vaccines into an increasingly globalized health market creates an increasing demand for robust and timely vaccine safety monitoring systems.

The introduction and impact of successful vaccines and public health implementation programs have been paralleled by advances in communication technologies which have coalesced to raise societal expectations for vaccine safety.

Dr Walter Straus, Associate Vice President, Therapeutic Area Head, Clinical Safety and Risk Management, Merck Research Laboratories


The role of emerging markets in the global supply and demand for vaccines: Perspectives from Brazil

Paving the way for a Dengue vaccine in Brazil

Soliciting support for sound scientific endeavors

Developing the framework for their realization, and reaching out for international partners

Dr Jorge Kalil, Former director of Butantan Institute, Professor and Head Clinical Immunology, School of Medicine, University Of Sao Paulo


The role of veterinary vaccines in the emergency management of a foreign animal disease outbreak

Dr Darrel Styles, Senior Staff Veterinarian,U.S.D.A. A.P.H.I.S. Veterinary Services


Next generation biomarkers for the era of precision cancer immunotherapy

Steven Townson, Principal Scientist, Clinical Research Oncology Early Development, Merck & Co


Accelerating vaccine development & biomanufacturing using a universal, non-viral delivery platform for engineering of relevant cell types

Rapidly express mg to gram quantities of MAbs, recombinant proteins, viral vectors, and VLPs

Bench to bedside scalability in cells relevant to bioproduction (CHO, HEK, Vero, MDCK, BHK21, insect cells, etc.)

Synergize and streamline migration from transient expression to stable cell line generation

Senior representative, Maxcyte


Results of a PhIa study of a universal influenza vaccine in healthy adults

The promise of prevention: A novel universal vaccine virus Protection from drifted or mismatched flu strains

Breadth of protection in multiple age groups


The AAVLP platform for prophylactic and therapeutic vaccines with special focus on HPV-L2

Adeno Associated Virus Like Particles as a vaccine platform.

Broad coverage HPV vaccine without adjuvant, targeting the L2 minor capsid protein.

Prophylactic and therapeutic AAVLP-HER2/Neu vaccine.

Dr John Nieland, Chief Operating Officer, 2A Pharma


Networking coffee break





CDC’s post-licensure vaccine safety monitoring systems – addressing 21st century public health needs

The Centers for Disease Control and Prevention (CDC) conducts post-licensure vaccine safety monitoring of licensed vaccines in U.S. children, adolescents and adults.

The three CDC post-licensure monitoring systems are the Vaccine Adverse Event Reporting System (VAERS), Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) Project. The functions of these systems complement each other and include passive surveillance (VAERS), active surveillance (VSD), clinical and epidemiologic research (VSD and CISA), and individual patient-level clinical case vaccine safety evaluations (CISA).

Overview of CDC’s post-licensure vaccine monitoring systems and describe some examples of how the systems have worked together to advance our understanding of vaccine safety.

Dr Karen Broder, Medical Officer, US Centers for Disease Control and Prevention


Improved potency & immunogenicity of Sci-B-Vac in support of phase III evaluation in adult populations

Dr Francisco Diaz-Mitoma, Chief Medical Officer, VBI Vaccines


Operational considerations for global respiratory studies – Using seasonality to guide study execution

Dr Cheryl Keech, Executive Medical Director,PPD


Overview Phase 2 progress with a measles vectored Chikungunya vaccine candidate, and implications for the development of this vector platform

Dr Erich Tauber, Chief Executive Officer and Founder, Themis Bioscience


Rolling out cold chain innovations on a larger scale

Experience gained from implementing the greatest revitalization of the cold chain in decades

Spreading innovation:

What does it take to roll out on a large scale?

What are the challenges in reaching so many countries

How the roll out is managed between partner organizations

Thomas Sorensen, Senior Manager, Cold Chain, Supply Division, Unicef


Targeting cancer through SurVaxM, a new peptide immunotherapeutic vaccine

SurVaxM is a synthetic long peptide (SLP) vaccine with incorporated peptide mimic technology

Engineered to trigger a stronger immune response than wild type peptide, through better MHC binding 

Completed Phase 1 clinical trial in recurrent glioblastoma

Interim phase 2 data and designing a phase 3 trial

Exploring other indications and combination therapies

Dr Michael Ciesielski, Assistant Professor of Neurosurgery & Oncology, Roswell Park Cancer Institute


Partnerships for global health: Redefining areas of the vaccine business that don’t attract commercial interest and revenue

How new international partnerships in different markets can help you find new alternative investments

Going beyond science: Moving to where the people are to redefine the vaccine business model

Dr Steven Reed, President, Founder & CEO,Infectious Disease Research Institute


The need for a Nipah virus (NiV) vaccine - What are the challenges and why now?

Current platform review of soluble glycoprotein vaccines and virus vector platforms

Exact correlates of protection against NiV have not been completely defined

Sporadic nature of NiV outbreaks makes large scale Phase III clinical trials difficult to plan - how will we overcome this?

Professor Thomas Geisbert, Professor Microbiology and Immunology, University of Texas Medical Branch


A rationally designed therapeutic consortium reshapes the gut microbiota and induces peripheral immune tolerance to protect from allergic asthma

Dr Benjamin Fiebiger, Senior Scientist, Lead Immunologist, Siolta Therapeutics


Vaccine self-sufficiency and responding to pandemic outbreaks from small to large scale

Understanding in securing strains, safety,  regulatory hurdles and manufacturing hurdles

Considering the logistics of distribution

Peter Khoury, CEO, Ology Bioservices




Clinical data from our pandemic influenza mRNA vaccines (H7N9 and H10N8)

Dr Giuseppe Ciaramella, Chief Scientific Officer, Infectious Diseases, Moderna Therapeutics


Discussion: Linking supply chains to immunization registries at home and abroad

In the USA:

The U.S. Vaccines for Children program move to centralized distribution and the need to automate the ordering process

How IIS are used to monitor vaccine usage, project vaccine needs, budget for future needs and monitor storage environments


The need to have systems that provide routine program data as well as supply chain data

The integration, interoperability & data sharing of these systems with examples in Tanzania and Zambia

How has the linkage of systems allowed the tracking of stock levels and projection of accurate usage rates for more efficient ordering and distribution

Ms Rebecca Coyle, Executive Director,American Immunization Registry Association

Laurie Werner, Global Director, BID Initiative,PATH


Immunosenescence: A growing population & an increasing unmet problem

Senior representative, Bioclinica Research Network


Legislating vaccines? A comparative look at the role of law in different countries in promoting vaccination

A comparison of international approaches to enforce vaccination

The current state of vaccination legislation in the USA

Dr Dorit Rubinstein Reiss, Professor of Law, UC Hastings College of the Law

Dr Jason Schwartz, Assistant Professor of Health Policy, Yale School of Public Health

Dr Margie Danchin, Paediatrcian and Senior Research Fellow, Murdoch Children's Research Institute, Royal Children's Hospital

Dr Marta Tomasi, Post-doc researcher, Free University of Bozen Bolzano


Panel Discussion: Tumor neoantigEn SeLection Alliance (TESLA) – discovering the keys to developing personalized cancer vaccines

Accurately identifying neo-epitopes

What is the diversity of neo-epitope predictions from different groups?

How well did these predictions perform in terms of patient sample analysis?

Can we identify key parameters that improve the ability to predict neo-epitopes?

How do we convert this data into the creation of personalized cancer vaccines?

Merits of different vaccines platforms

Dr Nina Bhardwaj, Director of Immunotherapy Professor of Medicine, Division of Hematology & Oncology, Tisch Cancer Institute

Dr Nir Hacohen, Director of the Center for Cancer Immunology and Co-Director of the Center for Cell Circuits, Broad Institute and Massachusetts General Hospital

Dr Robert Seder, Chief of the Cellular Immunology Section, NIAID, NIH

Dr Fred Ramsdell, Vice President, Research,Parker Institute for Cancer Immunotherapy


Stockpiling heat stable oral vaccines to combat emerging disease

Dr John A. Howard, President, Applied Biotechnology Institute


A double perspective from both sides: How to foster vaccine partnerships

Lesson learned in global access agreements

Catalytic funding

Partner to be announced

Dr Peter Dull, Deputy Director, Integrated Clinical Vaccine Development, The Bill & Melinda Gates Foundation

Dr Li Shi, Chief Executive Officer, Shanghai Zerun Biotechnology Co Ltd


Mucosal PRRSV vaccine for swine


A new paradigm for vaccine process development: solving challenges through supplier-manufacturer collaborations

Reserved for Millipore Sigma

Ranjeet Patil, Global Segment Marketing Manager, MilliporeSigma


Encouraging results from clinical studies for a HIV vaccine


Preparing for a pandemic: successful planning and distribution of large quantities of vaccine within a limited time frame

style="font-family: calibri light,sans-serif;">

             Long term relationships with potential pandemic countermeasure suppliers

             Regular planning and response communication with contractual partners and stakeholders.

             Advanced development work focusing on potential threats

             Vetted and approved response, modeling, capability and capacity plans

Geoffrey Glauser, Senior Consultant Supply Chain, HHS - ASPR - BARDA


Rapid protection & immunization against the next airborne pandemic

Infectious diseases emerge and mutate with high frequency

Conventional vaccination strategies take too long to positively affect the outcome of pandemics

We present an innovative technology to address the required rapidity and avoid selection of protective antigens

The device has been tested with both bacterial and viral pathogens and data from a study with influenza will be presented

Nigel Silman, Senior Business Development Manager, Public Health England


Uniting Saudi MERS clusters and controlling the continuing outbreak

Dr Maria Elena Bottazzi, Co-Director, Texas Children’s Hospital Center for Vaccine Development, Baylor College of Medicine

Dr Mazen Hassanain, Founder, SaudiVax


How to fund and develop vaccines for overlooked diseases? Insights on how a biotech should approach big organisations for a partnership deal

How to position yourself to the different pharma companies and investors to gain maximal funding and options

Deal structure and alliance management

Nima Farzan, Chief Executive Officer, PaxVax Inc


Nobivac® canine flu bivalent vaccine

Merck Animal Health’s response to CIV H3N2 outbreak in Chicago

CIV H3N2 infection in dogs

First vaccine to aid in the control of disease associated with both canine influenza virus (CIV) H3N2 and canine influenza virus H3N8

Efficacy study results

Next steps

Dr Rhonda LaFleur, Principal Scientist, Merck Animal Health


Panel: Manipulating the immune response with microbiome derived immunotherapies

Panellists to be announced shortly


Continuous Process for Vaccine Manufacturing: Challenges and opportunities

Experiences & lessons learned from the industry on continuous processing

Disposable technology & continuous technology: a powerful combination

Rapid technology advancement for key enablers to support continuous processing

FDA Fully on Board with the Concept of continuous processing

Dr Yan-ping Yang, Senior Director, Head of Bioprocess R&D North America, Sanofi Pasteur


Phase 2 influenza vaccine shows broad cross-protection and superiority in nonclinical heterologous challenge

Dr Thomas Muster, Managing Director and Chief Scientific Officer, Vivaldi Biosciences Inc


Chair’s closing remarks and close of congress day 2

Apr 5   


Chair’s opening remarks

Dr Myron M. Levine, Grollman Distinguished Professor and Director, Center for Vaccine Development, University of Maryland School of Medicine


Chair’s opening remarks

Dr George Siber, CSO of ClearPath Vaccines & Scientific Advisory Board of Genocea,ClearPath Vaccines


Chair’s opening remarks

Dr Niranjan Sardesai, COO, Inovio Pharmaceuticals


Chair’s opening remarks


Chair’s opening remarks


Chair’s opening remarks

Dr Neal Halsey, Professor of International Health, Director of the Institute for Vaccine Safety, Johns Hopkins


Chair’s opening remarks

Dr Cyril G Gay, Senior National Program Leader, A.R.S. National Programs


Chair’s opening remarks


Chair’s opening remarks

Dr Basav Ghosh, Sr. Director, Pfizer

Dr Bo Arve, Executive Director, Pfizer











DNA vaccines for cancer immunotherapy

Introduction to DNA plasmid and electroporation delivery technology

Updates in proof of concept studies from various trials

Head and neck cancer, bladder cancer, prostate cancer

Examples of potential combination partners

The regulatory landscape for DNA Vaccines

Dr Ildiko Csiki, Vice President - Clinical Development, Inovio Pharmaceuticals


Ensuring safety during outbreaks; the EBOLA experience

Challenges in vaccine clinical trials during public health emergencies

Ebola case study

Dr Ashley Wivel, Executive Director, Global Clinical Safety and Risk Management, Global Safety Physician for Ebola Vaccine Program,Merck Research Laboratories


Results on developing a new pertussis vaccine – Opportunities for maternal

·         The need for a new pertussis vaccine with longer lasting immunity

·         Challenges in making an effective pertussis vaccines: Cyclical by nature, waning immunity, asymptomatic carriers

Dr Rino Rappuoli, Chief Scientist, GSK Vaccines


The importance of supply chain security – counterfeiting, product theft and vaccine-specific concerns

The big picture: why is supply chain security so important?

Specific security concerns in vaccine supply for developing countries

Alternative distribution infrastructure

The ease of obtaining counterfeit vaccines

Strategies to prevent counterfeiting 

Reggie Jackson, Senior Manager of Supply Chain Security, Pfizer


Using a core endotoxin vaccine (J5) to fight the increasing spread of multidrug-resistant (MDR) gram-negative bacterial (GNB) infections

Directing a vaccine against the conserved LPS core (lipooligosaccharide, LOS) region of GNBs as a highly effective and protective target

Two Ph1 trials showing how well-tolerated and non-reactogenic the vaccine was as well as high immunogenic levels when administered with CPG 7909 adjuvant

Future applications to generate antibodies for the treatment of a broad range of MDR GNB infections

How could the vaccine affect the microbiome?

Dr Alan Cross, Professor of Medicine,University of Maryland School of Medicine


Will a new 2018 global leadership commit to NTDs?

·         How will the shift in global governance from 2017 (in the UN, WHO, US president and UK prime minister) affect the global support for NTDs?

·         What does our community of NTD scientists, public health experts, and health care providers want this new global leadership to know about our diseases?

·         What should they prioritize?

Dr Peter Hotez, Dean, National School of Tropical Medicine, Director, Texas Children’s Hospital Center, Baylor College of Medicine


Role of vaccines in preventing further AMR - The big push

What are the incentives for industry?

Proposed diseases where development or improvement of vaccines would have a high impact on antibiotic use

Creating global vaccine research networks to pull resources and expertise to address gaps for priority diseases

Kemal Karaca, Director, Elanco Animal Health


Panel: Engineering CAR-T & TCR cells for cancer therapy

How can you additionally modify T-cells beyond the T cell receptor/ the CAR to behave in a more controlled and/or potent fashion?

The challenge of keeping the manufacturing process simple, whilst maintaining the effectiveness of the product

The use of molecular imaging to track CAR T cells: Where do they go in the body? Do they accumulate in the tumor?

Mitigating side effects: controlling neurotoxicity etc.

Biomarkers – Identifying patients that will respond to treatment

Combination strategies

Dr Hyam Levitsky, Executive Vice President and Chief Scientific Officer, Juno Therapeutics

Dr Laurent Poirot, Head of Early Discovery,Cellectis

Dr Margo R. Roberts, Chief Scientific Officer,Kite Pharma Inc

Jennifer Brogdon, Director of Exploratory Immuno Oncology, N.I.B.R.

Dr Samik Basu, Director of Translational Sciences, Adaptimmune Llc


Understanding how vaccines elicit immune responses

Prof Fikri Avci, Academy, UGA Center for Molecular Medicine


Archaeal lipid adjuvants and adenovirus vector delivery systems for cancer vaccine delivery Sulfated semi-synthetic archaeal lipids are potent modulators of vaccine immunity

A single lipid formulation can effectively deliver cancer antigens and provide protection in cancer models

Therapeutic benefit can be extended through combination vaccines with adenoviral vector antigen delivery and check-point inhibitor blockade

Dr Lakshmi Krishnan, Group Leader-Senior Research Officer, National Research Council


Bioconjugate Shigella vaccine in clinical development

·         The development plan for a Shigella vaccine demonstrated in PhI and a PhIIB human challenge study

·         A regulatory tool for licensing

Dr Veronica Gambillara Fonck, Co-Founder & Chief Executive Officer, LimmaTech Biologics AG


Immune profiling techniques to help develop a more effective pertussis vaccine

Dr Alessandro Sette, Professor, Head and Member, La Jolla Infectious Disease Institute


Supply disruptions – how to limit impact of supply disruptions on country vaccination programs

A closer look at the causes of the recent hepatitis vaccine shortage

Measures taken to avoid disruptions in supply

Potential solutions to avoid disruption from future shortages

Should other countries be stock piling?

How practical is this?

William Conklin, Value Chain Leader, Merck Vaccines


The science of causality assessment

The science of causality assessment is poorly understood by healthcare providers and the general public

Temporal relationships and hypotheses regarding mechanisms are not sufficient to establish causality

Journals should establish standard criteria for publishing case reports of alleged causal relationships

Decisions to compensate for alleged vaccine injuries should be based on science

Safety profiles may vary in different populations

All countries should have formal vaccine safety programs

Dr Neal Halsey, Professor of International Health, Director of the Institute for Vaccine Safety, Johns Hopkins


Update on Group B streptococcal maternal immunization program

Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer


Advancements made in bacterial vaccines

Technologies for identification of antigens

Novel vaccine formulations

Dr Andrew Potter, CEO, VIDO-InterVac


Enabling translation of vaccine discovery into clinical candidates in academia

Dr Frederick Porter, Senior Director of Product Development, Duke Human Vaccine Institute


Overcoming the limitations of viral vectors whilst still maintaining superior generation and expansion of CTLs


Chair's opening remarks

Dr Eliav Barr, Senior Vice President, Infectious Diseases and Vaccines Clinical Development,Merck Research Laboratories


Densigen, a versatile immunotherapeutic platform to promote broad and robust T cell immunity against viral infections and cancer

Densigens are rationally designed, CD4+/CD8+ T cell epitope-containing peptides modified by a fluorocarbon moiety providing self-adjuvanting properties

Densigen-based immunotherapeutics promote robust T cell responses in humans while achieving broad population coverage

Densigens simultaneously target multiple antigenic determinants to prevent immune escape

Prime-boost immunizations with Densigens can act synergistically to promote better T cell responses

Dr Scot Roberts, Chief Scientific Officer,Altimmune


How could needle free vaccines change the way vaccines can be distributed and perceived in response to an emerging disease?

Dr Erin Spiegel, Regulatory Affairs Manager,PharmaJet


Unplanned parainfluenza virus infection on an isolation ward – A case study

In this presentation a case of unplanned Parainfluenza Virus (PIV) is discussed with possible routes of acquisition and its effects on study data. Also the potential limitations of early diagnosis in preventing commonly circulating, community diseases infecting those entering or already housed in containment facilities

Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Infection Unit, SGS Life Science Services


Update on next-generation pneumococcal vaccines

Dr George Siber, CSO of ClearPath Vaccines & Scientific Advisory Board of Genocea,ClearPath Vaccines


What can vaccines learn from neglected diseases on effectively engaging the private sector?

Introduction to NTDs and shared components with immunization – how are the programs components are similar?

Development of global partnership: Uniting to Combat NTDs

Relationship with pharma is critical

Examples of success stories:

supply chain and logistics coordination

Julie Jacobson, Senior Program Officer, Neglected Tropical Diseases, The Bill & Melinda Gates Foundation


How early stage vaccine application aids decrease in the use of antibiotics, either for preventive or curative purposes in poultry

Benefits of early control in immunosuppressive poultry diseases

Application of vaccines at early stages of development, for example day 18 of age embryos for in ovo, or day old at hatch  

Dr Stéphane Lemiere, Global Director of Technical Services, Boehringer Ingelheim France


Combinatorial immunotherapy: expanding the horizons with bispecific DART® molecules

Dr Ezio Bonvini, CSO, MacroGenics, Inc.


Designing vaccines focusing on critical quality attributes and analytical strategies

Dr Fiona Lin, Small Molecule Analytical Chemistry and Quality Control, Genentech


HiA; A vaccine solution to address an urgent public health need

Dr Andrew Cox, Senior Research Officer,National Research Council


Networking coffee break


Development of a Combined Shigella-ETEC Live Vaccine

Dr Eileen Barry, Professor of Medicine,University of Maryland School of Medicine


Novel multivalent vaccine for gram-negative bacterial pathogens, including multiple antibiotic-resistant strains

Dr Raphael Simon, Assistant Professor of Medicine, University of Maryland School of Medicine


Panel: Innovation, emerging technology and digitalization in vaccine supply chains

Panellists to be announced shortly

Charles Heffernan, Former Supply Chain Transformation and Technology Innovation Lead, GSK & Member, BioPhorum Operations Group

Mohit Chopra, Senior Manager of USOTC Supply Chain Strategic Improvement,Johnson & Johnson


Recent progress in clinical TB vaccine development

Dr Ann Ginsberg, Chief Medical Officer,AERAS


Safety assessment, communication of risk and interventions around acceptance in maternal immunization

Safety of TDaP and IIV vaccine

Emerging issues around 1st trimester vaccination, adverse outcomes and how this has informed acceptance

Dr Saad B Omer, William H. Foege Professor of Global Health Professor of Epidemiology & Pediatrics, Emory University - School of Medicine


Translational Studies Informing the Design and Feasibility of a vaccine against Epstein Barr Virus

Opportunities for the development of a vaccine against EBV

Understanding the medical necessity, market potential and public health use of EBV Vaccine.

The science behind the 3 vaccine candidates that currently exist:

Pre-clinical safety data

Updates on progress of phase 1 trials.

Dr Corey Casper, Chief Scientific Officer,Infectious Disease Research Institute


Panel:Alternatives to Antibiotics: Issues and opportunities from funders’ perspective

How to incentivise vet pharma companies to produce new veterinary products to reduce AMR resistance

Marketing the science and the costs associated with this

Statement of societal goals that the funding entity would like to accomplish

Political feasibility of incentive mechanisms (e.g., is a program that gives money to large pharma companies likely to be accepted by legislators?)

Economics of incentive mechanisms (e.g., which incentive ‘lever’ can be pushed for maximal effect?  What would unintended consequences of such incentives be?)

Franck Berthe, Senior Livestock Specialist, The World Bank

Dr Alex Morrow, Chair of the International Research Consortium, STAR-IDAZ International Research Consortium on Animal Health

Dr Jean-Charles Cavitte, Research Policy Officer, European Commission

Samuel Thevasagayam, Deputy Director, Global Development, The Bill & Melinda Gates Foundation

Stacy Sneeringer, Senior Research Economist,Economic Research Service United States Department of Agriculture USDA


Cancer neoantigens and their use in personalized cancer vaccines


Developing vaccines for developing countries – A case study on Typhoid conjugate vaccine

Dr Viliam Pavliak, Head of Vaccine Development, International Vaccine Institute


Advances in the development of a replication-deficient human cytomegalovirus vaccine for the prevention of congenital infection

The Burden of Disease caused by maternal/fetal/infant CMV infection

Natural History of maternal/fetal/infant CMV infection

Merck’s CMV vaccine candidate

Strategies to demonstrate the efficacy and safety profiles of CMV vaccines targeted to prevent congenital CMV infection

Dr Eliav Barr, Senior Vice President, Infectious Diseases and Vaccines Clinical Development,Merck Research Laboratories


H1N1 Pandemic flu vaccine, lessons in safety and communication learned from the 2009-10 vaccine program and lessons for future surveillance

What are the unique challenges in maintaining public confidence during a pandemic?

What safety monitoring system was used during the 2009-10 pandemic?

What lessons can be learned from the handling of this pandemic that can be applied to future outbreaks?

Dr Daniel Salmon, Prof Global Disease Epidemiology and Control; Deputy Director JHU’s Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health

Dr Karin Bok, Senior Vaccine Science Advisor,US Department of Health and Human Services


Presenting early stage development of a vaccine to prevent the bacterial infections that exacerbate Chronic Obstructive Pulmonary Disease (COPD)

·         COPD is a very common, chronic, progressive, respiratory illness of adults, which can be triggered by bacterial infections

·         A vaccine to prevent these respiratory infections could modify the clinical progression of COPD, and improve quality of life

Dr Simona Rondini, Vaccine Development Lead, COPD Vaccine, GSK Vaccines


Strategies for developing vaccines against Paratyphoid A fever

Dr Sushant Sahastrabuddhe, Director, Enteric Fever, International Vaccine Institute


Tools to assess and advance Group A Streptococcus (GAS) Vaccines


Development of off-the-shelf immunotherapy from pluripotent cells

Pluripotent Cell Derived T and NK cells: Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy

Use of small molecules and biologics, ex vivo, to optimize the biological properties and therapeutic function of hematopoietic cells

Dr Bahram Bob Valamehr, Vice President of Cancer Immunotherapy, Fate Therapeutics


From development to commercialization of vaccines – a case study

Dr Dicky Abraham, Executive Director, Project Leadership Group, Global Vaccine and Biologics Commercialization, Merck


Networking Lunch & Poster Session



Chair’s opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation


Report on U.S. vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development

A combined effort from HHS, NIH, CDC, FDA, BARDA to promote innovation in the development of vaccines that minimize the burden of infectious disease

What is the optimal process to determine which vaccines would be beneficial to public health and how information on such vaccines is disseminated to key stakeholders

Identifying whether obstacles exist that inhibit the development of beneficial vaccines

Recommendations on how best to promote and incentivize vaccine innovation and development

Dr Angela Shen, CAPT, US Public Health Service, Senior Science Policy Advisor, National Vaccine Program Office, U.S. Department of Health & Human Services


Zoster vaccine recombinant, adjuvanted: A journey from research to approval

Non-live, recombinant vaccine to help prevent herpes zoster (shingles), combining glycoprotein E with an adjuvant system, AS01

Sharing positive results from Phase III revaccination study 

Dr Jeffrey Stoddard, US Medical Affairs Lead for Zoster Vaccine, GSK Vaccines


With polio eradication succeeding, should measles eradication come next?

Changing the perception from polio: Focusing on measles elimination to build our overall immunization program

Using a “diagonal” approach when dealing with highly contagious preventable diseases like measles

Surveillance -  a weakness in our system?

Cost of controlling outbreaks and the consequences

Dr Walter A Orenstein, Professor and Associate Director, Emory Vaccine Center Emory University


Vaccine hesitancy: How to respond to the media to advance better health

Challenges to communicating science through the opaque prism of the media

How certain cultural biases can influence the perception of science 

Dr Paul Offit, Chief of Infectious Diseases, & Director of the Vaccine Education Center, Childrens Hospital of Pennsylvania


3:40 Chair closing remarks and end of congress




MORE events +